Exchange: NASDAQ·Updated 04:40 PM EDT
News
all
press releases
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...
PR Newswire
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday
Coherus Oncology (NASDAQ:CHRS) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-coherus-biosciences-inc-stock...
MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200-Day Moving Average - Here's Why
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving Average - What's Next...
MarketBeat
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?
Here is how Brookdale Senior Living (BKD) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Time to Sell?
Coherus Oncology (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat reports. One...
MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving Average - Time to Sell...
MarketBeat

Advertisement|Remove ads.